Clinical Compound Library Plus - PartA

Sizes available:

10 mM *30µl; 10 mM *50µl; 10 mM *100µl; 2*10 mM *100µl; 10 mM *250µl

Please contact us for price or customized libraries!

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2430 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form. MCE Clinical Compound Library Plus can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1980 compounds supplied in 10 mM solution, 51 compounds supplied in 2 mM solution and 11 compounds supplied in 3 mg/mL solution. For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.